Literature DB >> 1682113

Duration of protection by inhaled salmeterol in exercise-induced asthma.

S D Anderson1, L T Rodwell, J Du Toit, I H Young.   

Abstract

Beta-adrenoceptor agonists such as albuterol are very effective in preventing exercise-induced asthma (EIA) when they are given as an aerosol immediately before exercise. However, their duration of protection against EIA is usually less than 2 h. This may be due partly to their rapid clearance from the airways. Salmeterol is a highly lipophylic compound that is thought to bind to an exoreceptor near the beta-receptor. The objective of this study was to compare the protective effect of salmeterol with albuterol against EIA. Exercise was performed 0.5, 2.5, 4.5, and 6.5 hours after administration of the active drugs. Subjects attended the laboratory on four days within six weeks and cycled for 8 min breathing dry compressed air. We studied 17 asthmatic subjects (aged 19 to 49 years) with moderate to severe EIA. Salmeterol (50 micrograms) or albuterol (200 micrograms) was given from a metered dose inhaler via a spacer (Volumatic). On the control day, the mean work load +/- 1 SD was 174 +/- 47 W, ventilation (VE) was 77.9 percent +/- 11.2 percent of the target ventilation (60 percent maximum voluntary ventilation [MVV]), and heart rate was 170 +/- 14 beats per minute. This intensity was maintained for all tests. FEV1 was measured before and after exercise and was expressed as percent predicted and as percentage of the preexercise value (percentage of fall). Thirty minutes after treatment, both drugs were effective in inhibiting EIA--percentage of fall in FEV1, 17 +/- 12 after salmeterol; percentage of fall in FEV1, 15 +/- 15 after albuterol. At 2.5, 4.5, and 6.5 hours, the reduction in FEV1 was significantly less (p less than 0.01) after salmeterol compared with albuterol. At 6.5 hours, the percentage of fall in FEV1 was 20 +/- 10 after salmeterol and 36 +/- 12 after albuterol. Salmeterol also had a more prolonged action as a bronchodilator and values for FEV1 were significantly higher compared with those on albuterol at 4.5 and 6.5 hours. At 6.5 hours, the FEV1 percent predicted was 96 +/- 10 after salmeterol and 84 +/- 12 after albuterol (p less than 0.01). We conclude that the extent of protection against EIA and the bronchodilation induced by both drugs was similar, but that salmeterol has a longer duration of action compared with albuterol. The reason for its superior duration of action may be due to a slower clearance of the drug from the airways.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682113     DOI: 10.1378/chest.100.5.1254

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

Review 1.  Making the diagnosis of asthma in the athlete.

Authors:  Chris Randolph
Journal:  Clin Rev Allergy Immunol       Date:  2005-10       Impact factor: 8.667

Review 2.  Effects of exercise training on airway hyperreactivity in asthma: a systematic review and meta-analysis.

Authors:  Philipp A Eichenberger; Stephanie N Diener; Reto Kofmehl; Christina M Spengler
Journal:  Sports Med       Date:  2013-11       Impact factor: 11.136

Review 3.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 4.  Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Authors:  R N Brogden; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

5.  Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attack.

Authors:  M Ritz; J B Thorens; M Arnold-Ketterer; J C Chevrolet
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

Review 6.  Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2003-02       Impact factor: 8.667

7.  Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.

Authors:  B Lundback; D W Rawlinson; J B Palmer
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

Review 8.  Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.

Authors:  J Lötvall; N Svedmyr
Journal:  Lung       Date:  1993       Impact factor: 2.584

Review 9.  Long-acting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist.

Authors:  James P Kemp
Journal:  Ther Clin Risk Manag       Date:  2009       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.